A White House crypto adviser just confirmed something that changes everything for XRP holders. The key blocker to the Clarity Act? Resolved. This isn't speculA White House crypto adviser just confirmed something that changes everything for XRP holders. The key blocker to the Clarity Act? Resolved. This isn't specul
White House crypto adviser confirms key Clarity Act blocker resolved, impacting XRP regulatory landscape.
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
A White House crypto adviser just confirmed something that changes everything for XRP holders. The key blocker to the Clarity Act? Resolved. This isn't speculation anymore. This is happening. 🧵
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
You May Also Like
Immutep (IMM) Stock Doubles on FDA Orphan Drug Win for Rare Cancer Drug
TLDR Immutep stock jumped over 101% on Wednesday after receiving FDA Orphan Drug Designation for eftilagimod alfa (efti). The designation covers soft tissue sarcoma
Share
Coincentral2026/04/15 20:09
XRP flashes golden cross signal: Is $5 next?
The post XRP flashes golden cross signal: Is $5 next? appeared on BitcoinEthereumNews.com. As XRP continues to consolidate, its technical structure is flashing
Share
BitcoinEthereumNews2026/04/15 20:34
Immutep (IMM) Shares Soar 101% Following FDA Orphan Drug Status for Cancer Therapy
Immutep (IMM) stock soared 101% after FDA granted Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma. Market exclusivity & tax benefits await.
Share
Blockonomi2026/04/15 20:19
